SPPH Stock Overview
Develops drug platform technologies for the treatment of neurological deceases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Spencer Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | 0% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SPPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | 0% | 18.8% | 32.3% |
Return vs Industry: SPPH underperformed the US Biotechs industry which returned 18.8% over the past year.
Return vs Market: SPPH underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| SPPH volatility | |
|---|---|
| SPPH Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SPPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine SPPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Max Arella | n/a |
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe.
Spencer Pharmaceutical Inc. Fundamentals Summary
| SPPH fundamental statistics | |
|---|---|
| Market cap | US$271.00 |
| Earnings (TTM) | -US$943.20k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs SPPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$943.20k |
| Earnings | -US$943.20k |
Last Reported Earnings
Dec 31, 2010
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did SPPH perform over the long term?
See historical performance and comparison